Company: DMAAR
Filing Date: 2025-08-14
Form Type: 10-Q
Source: 0001213900-25-076681
Chunk: 64

Company: Drugs Made In America Acquisition Corp.
Filing Date: 2025-08-14
Form: 10-Q
Item: Part I, Item 8
Chunk 64
---
 Public Offering, the Company recognized the accretion from initial book value to redemption amount value.
The change in the carrying value of redeemable shares will result in charges against additional paid-in capital and accumulated deficit.
Accordingly, as of June 30, 2025, ordinary shares subject to possible redemption is presented at redemption value as temporary equity,
outside of the shareholders’ deficit section of the Company’s unaudited balance sheets. Increases or decreases in the carrying
amount of redeemable shares are affected by charges against additional paid-in capital and accumulated deficit.

As of December 31, 2024, there were no shares
subject to possible redemption. As of June 30, 2025, the ordinary shares subject to possible redemption reflected in the unaudited balance
sheets are reconciled in the following table:

    Shares  
    Amount 
  
    Gross proceeds 
     20,000,000  
    $200,000,000 
  
    Less: 

    Proceeds allocated to Public Rights 
        
     (2,978,000)
  
    Proceeds allocated to over-allotment option 
        
     (305,179)
  
    Ordinary share issuance cost 
        
     (7,703,027)
  
    Plus: 

    Remeasurement of carrying value to redemption value 
        
     11,986,206 
  
    Ordinary shares subject to possible redemption, January 29, 2025 
     20,000,000  
    $201,000,000 
  
    Gross proceeds from exercise of over-allotment option 
     3,000,000  
     30,000,000 
  
    Less: 

    Proceeds allocated to Public Rights from exercise of over-allotment option 
        
     (446,700)
  
    Ordinary share issuance cost from exercise of over-allotment option 
        
     (1,047,367)
  
    Plus: 

    Exercise of over-allotment option 
        
     305,179 
  
    Remeasurement of carrying value to redemption value 
        
     2,924,356 
  
    Ordinary shares subject to possible redemption, March 31, 2025 
     23,000,000  
    $232,735,468 
  
    Plus: 

    Remeasurement of carrying value to redemption value